Novartis | NOVN - DEBITO





DEBITO Cambiamento Data
AbbVie USD 72.86B 5.36B 2026-03
Alcon AG USD 5.25B 4.74B 2026-03
Almirall EUR 342.86M 61.94M 2025-12
Amgen USD 57.32B 2.72B 2026-03
AstraZeneca USD 32.24B 1.68B 2026-06
Autolus Therapeutics Ltd USD 253.44M 8.84M 2025-03
Bayer EUR 36.45B 2.93B 2025-12
Biogen USD 8.09B 1.53B 2026-06
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Eli Lilly USD 43.37B 867M 2026-03
Fresenius EUR 11.9B 28M 2026-03
Fresenius Medical Care EUR 10.96B 66.06M 2026-06
Genmab DKK 5.35B 5.2B 2026-03
Gilead Sciences USD 22.17B 2.76B 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
GRIFOLS EUR 8.52B 1.15B 2026-06
Hikma Pharmaceutical USD 1.6B 46M 2025-12
J&J USD 54.99B 7.05B 2026-03
Lakefront Biotherapeutics EUR 6.44M 480K 2026-03
Lonza CHF 4.71B 915M 2024-12
Merck EUR 12.04B 86M 2026-03
Merck USD 49.12B 222M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Novartis USD 47B 14.98B 2026-03
Novo Nordisk DKK 118.72B 61.75B 2025-03
Orion EUR 330.3M 24.9M 2026-03
Pfizer USD 63.19B 536M 2026-06
Philips EUR 7.47B 632M 2026-06
Recordati EUR 2.31B 57.06M 2026-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 23.58B 3.56B 2026-06
UCB EUR 3.03B 12M 2024-12